Physician profile
Scott Thomas Miles
NPI 1073512125
$886.57
in general payments reported to CMS, 2019-2025
14 companies · $709 in 2025
The $709 reported for 2025 was more than what 91% of Addiction Medicine (Preventive Medicine) providers received nationally (typical 2025 total: $115).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $17.69 · 2020: $48.04 · 2024: $112 · 2025: $709.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $821.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $820.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Collegium Pharmaceutical, INC. | $184.51 | 2025 | Belbuca, Xtampza |
| Braeburn INC. | $127.15 | 2025 | Brixadi |
| Indivior INC. | $107.86 | 2019-2025 | Sublocade |
| Medtronic, INC. | $74.12 | 2025 | Intellis Adaptivestim |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $59.11 | 2024-2025 | Relistor |
| Vertex Pharmaceuticals Incorporated | $52.07 | 2025 | |
| Abbvie INC. | $48.25 | 2024-2025 | |
| Boston Scientific Corporation | $48.04 | 2020 | |
| Orexo US, INC. | $41.07 | 2024-2025 | Zubsolv |
| Valinor Pharma, LLC | $40.85 | 2025 | Movantik |
| Solventum Corporation | $34.02 | 2025 | V.A.C. Veraflo, Promogran Prisma, Prevena |
| Globus Medical, INC. | $31.62 | 2025 | Senza |
| Protega Pharmaceutials INC | $22.90 | 2025 | Roxybond |
| Forte Bio-Pharma LLC | $15.00 | 2024 | Prolate, Nalocet |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Miles listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.